REFERENCES
1. Zhou Y, Ingelman-Sundberg M, Lauschke VM. Worldwide Distribution of
Cytochrome P450 Alleles: A Meta-analysis of Population-scale Sequencing
Projects. Clin Pharmacol Ther . 2017;102(4):688-700.
doi:10.1002/cpt.690
2. Thase ME, Mahableshwarkar AR, Dragheim M, Loft H, Vieta E. A
meta-analysis of randomized, placebo-controlled trials of vortioxetine
for the treatment of major depressive disorder in adults. Eur
Neuropsychopharmacol . 2016;26(6):979-993.
doi:10.1016/j.euroneuro.2016.03.007
3. Chen G, Højer AM, Areberg J, Nomikos G. Vortioxetine: Clinical
Pharmacokinetics and Drug Interactions. Clin Pharmacokinet .
2018;57(6):673-686. doi:10.1007/s40262-017-0612-7
4. Caudle KE, Sangkuhl K, Whirl-Carrillo M, et al. Standardizing CYP2D6
Genotype to Phenotype Translation: Consensus Recommendations from the
Clinical Pharmacogenetics Implementation Consortium and Dutch
Pharmacogenetics Working Group. Clin Transl Sci .
2019;13(1):116-124. doi:10.1111/cts.12692
5. Jukić MM, Haslemo T, Molden E, Ingelman-Sundberg M. Impact of CYP2C19
genotype on escitalopram exposure and therapeutic failure: A
retrospective study based on 2,087 patients. Am J Psychiatry .
2018;175(5):463-470. doi:10.1176/appi.ajp.2017.17050550
6. Jukic MM, Smith RL, Haslemo T, Molden E, Ingelman-Sundberg M. Effect
of CYP2D6 genotype on exposure and efficacy of risperidone and
aripiprazole: a retrospective, cohort study. The Lancet
Psychiatry . 2019;6(5):418-426. doi:10.1016/S2215-0366(19)30088-4
7. Areberg J, Petersen KB, Chen G, Naik H. Population Pharmacokinetic
Meta-Analysis of Vortioxetine in Healthy Individuals. Basic Clin
Pharmacol Toxicol . 2014;115(6):552-559. doi:10.1111/bcpt.12256
8. US Drug label. TRINTELLIX (vortioxetine) tablets, for oral use.
Available at:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/204447s017lbl.pdf.
9. Hiemke C, Bergemann N, Clement HW, et al. Consensus Guidelines for
Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017.Pharmacopsychiatry . 2018;51(1-2):9-62. doi:10.1055/s-0043-116492
Table 1 Summary of patient characteristics and information
related to the TDM analyses of vortioxetine and antidepressant switch
frequencies according to CYP2D6 metabolizer phenotype